Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2019

Open Access 01-10-2019 | Breast Cancer | Breast Oncology

Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons

Authors: Eric R. Manahan, MD, MBA, Henry M. Kuerer, MD, PhD, Molly Sebastian, MD, Kevin S. Hughes, MD, Judy C. Boughey, MD, David M. Euhus, MD, Susan K. Boolbol, MD, Walton A. Taylor, MD

Published in: Annals of Surgical Oncology | Issue 10/2019

Login to get access

Abstract

Background

The purpose of this consensus guideline is to outline recommendations for genetic testing that medical professionals can use to assess hereditary risk for breast cancer.

Methods

Literature review included large datasets, basic and clinical science publications, and recent updated national guidelines. Genetic testing to assess hereditary risk of cancer is a complex, broad, and dynamic area of medical research. The dominant focus of this guideline is limited in scope to breast cancer.

Results

There is a lack of consensus among experts regarding which genes among many should be tested in different clinical scenarios. There is also variation in the degree of consensus regarding the understanding of risk and appropriate clinical management of mutations in many genes.

Conclusions

Genetic testing should be made available to all patients with a personal history of breast cancer. Recent data are reviewed that support genetic testing being offered to each patient with breast cancer (newly diagnosed or with a personal history). If genetic testing is performed, such testing should include BRCA1/BRCA2 and PALB2, with other genes as appropriate for the clinical scenario and family history. For patients with newly diagnosed breast cancer, identification of a mutation may impact local treatment recommendations. Patients who had genetic testing previously may benefit from updated testing. Genetic testing should be made available to patients without a history of breast cancer who meet National Comprehensive Cancer Network guidelines. Finally, variants of uncertain significance are not clinically actionable and these patients should be managed based on their individual risk factors.
Literature
1.
Plichta, J, Sebastian, M, Hughes, K, et al. Germline genetic testing: what the breast surgeon needs to know. Ann of Surg Oncol. 2019;26:2184–90.CrossRef
2.
3.
4.
Castera L, Krieger S, Rousselin A, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 2014;22:1305–13.CrossRefPubMedPubMedCentral
5.
Walsh T, Lee MK, Casadei S, et al. Detection of inherited pathogenic variants for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA. 2010;107:12629–33.CrossRefPubMed
6.
7.
8.
Meindl A, Ditsch N, Kast K, Schmutzler RK. Hereditary breast and ovarian cancer: New genes, new treatments, new concepts. Dtsch Arztebl Int. 2011;108:323–30.PubMedPubMedCentral
9.
10.
Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 pathogenic variant carriers with cancer risk and mortality. JAMA. 2010;304:967–75.CrossRefPubMedPubMedCentral
11.
Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 pathogenic variant. N Engl J Med. 2002;346:1609–15.CrossRefPubMed
12.
Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene pathogenic variant carriers. J Natl Cancer Inst. 2001;93:1633–7.CrossRefPubMed
13.
Kurian AW, Sigal BM, Plevrittis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 pathogenic variant carriers. J Clin Oncol. 2010;28:222–31.CrossRefPubMed
14.
Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol. 2005;23:1656–63.CrossRefPubMed
15.
Eisen A, Lubinski J, KlijnJ, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers: international case-control study. J Clin Oncol. 2005;23:7491–6.CrossRefPubMed
16.
Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 pathogenic variant carriers: a case-control study. Lancet. 2000;356:1876–81.CrossRefPubMed
17.
Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 pathogenic variants. N Engl J Med. 2002;346:1616–22.CrossRefPubMed
18.
Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: The PROSE Study Group. J Clin Oncol. 2004;22:1055–62.CrossRefPubMed
19.
Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2018;37:1–8.
20.
Yang S, Axilbund JE, O’Leary E, et al. Underdiagnosis of hereditary breast and ovarian cancer in Medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol. 2018;25:2925–31.CrossRefPubMed
21.
Kurian et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019:37;1305–15.CrossRefPubMed
22.
23.
Kapoor NS, Curcio LD, Blakemore CA, et al. Multigene panel testing detects equal rates of pathogenic BRCA1/2 pathogenic variants and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol. 2015;22:3282–8.CrossRefPubMed
24.
Domchek, SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31:1267–70.CrossRefPubMed
25.
26.
Pierce LJ, Haffty BG. Radiotherapy in the treatment of hereditary breast cancer. Semin Radiat Oncol. 2011;21:43–50.CrossRefPubMed
27.
Sikov WM. Assessing the role of platinum agents in aggressive breast cancers. Curr Oncol Rep. 2015;17:3.CrossRefPubMed
28.
29.
30.
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 pathogenic variants detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.CrossRefPubMedPubMedCentral
31.
Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318–24.CrossRefPubMed
32.
Schmidt MK, Hogervorst F, van Hien R, et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. J Clin Oncol. 2016;34(23):2750–60.CrossRefPubMedPubMedCentral
33.
34.
35.
36.
37.
38.
Nelson H, Pappas M, Zakher B, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014;160:255–66.CrossRefPubMed
39.
Rainville IR, Rana HQ. Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. Curr Oncol Rep. 2014;16:371.CrossRefPubMed
40.
Ku CS, Cooper DN, Iacopetta B, et al. Integrating next generation sequencing into the diagnostic testing of inherited cancer predisposition. Clin Genet. 2013; 83:2–6.CrossRefPubMed
41.
Simen B, Yin L, Goswami C, et al. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory. Arch Pathol Lab Med. 2015;139:508–17.CrossRefPubMed
42.
Association for Molecular Pathology v Myriad Genetics, Inc., 569 US (2013).
43.
Azvolinsky A. Supreme Court ruling broadens BRCA testing options. J Natl Cancer Inst. 2013;105:1671–72.CrossRefPubMed
44.
LaDuca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med. 2014;16:830–7.CrossRefPubMedPubMedCentral
45.
Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32:2001–9.CrossRefPubMedPubMedCentral
46.
Tung N, Battelli C, Allen B, et al. Frequency of pathogenic variants in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121:25–33.CrossRefPubMed
47.
Yorczyk A, Robinson LS, Ross TS. Use of panel tests in place of single gene tests in the cancer genetics clinic. Clin Genet. 2015;88:278–82.CrossRefPubMed
48.
King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA. 2014;312:1091–2.CrossRefPubMed
49.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.CrossRefPubMedPubMedCentral
Metadata
Title
Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons
Authors
Eric R. Manahan, MD, MBA
Henry M. Kuerer, MD, PhD
Molly Sebastian, MD
Kevin S. Hughes, MD
Judy C. Boughey, MD
David M. Euhus, MD
Susan K. Boolbol, MD
Walton A. Taylor, MD
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 10/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07549-8

Other articles of this Issue 10/2019

Annals of Surgical Oncology 10/2019 Go to the issue

Breast Oncology

Presidential Address: On Resisting the Narcissism of the Present

Breast Oncology

Distress: Characterizing What Causes the Thermometer to Shift in Patients with Newly Diagnosed Breast Cancer Attending a Multidisciplinary Clinic

Breast Oncology

The Standardization of Outpatient Procedure (STOP) Narcotics: A Prospective Health Systems Intervention to Reduce Opioid Use in Ambulatory Breast Surgery

Breast Oncology

Sexual Dysfunction in Survivorship; the Impact of Menopause and Endocrine Therapy

Scientific Presentation Award

Physician Knowledge of Breast Cancer Recurrence and Contralateral Breast Cancer Risk is Associated with Increased Recommendations for Contralateral Prophylactic Mastectomy: a Survey of Physicians at NAPBC-Accredited Centers

Breast Oncology

Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons